Julian Baker’s Sarepta Therapeutics SRPT Stock Holding History

Julian Baker’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-123,456	Closed	-$9.64M	–	122
2022 Q1	$9.64M	Hold	123,456	–	–	0.06%	68
2021 Q4	$11.1M	Buy	+123,456	New	+$10.6M	0.05%	74
2021 Q2	–	Sell	-58,700	Closed	-$4.38M	–	127
2021 Q1	$4.38M	Buy	+58,700	New	+$5.42M	0.02%	99

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Julian Baker's SRPT Position: Q2 2022 in Review

Julian Baker sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 123,456 shares — an estimated $9.64M sold.

Julian Baker first reported a position in SRPT in Q1 2021 and held it in 3 quarters. The position peaked at $11.1M in Q4 2021. 332 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

Julian Baker reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
Julian Baker sold 123,456 Sarepta Therapeutics shares in Q2 2022, an estimated $9.64M.
Julian Baker first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 3 quarters.
Julian Baker's Sarepta Therapeutics position peaked at $11.1M in Q4 2021.
332 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.